📰 Nasdaq Huma News
Page 2 - Nasdaq Huma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Huma. Real-time updates on events, politics, business and more.
January 6, 2024
Humacyte (NASDAQ:HUMA – Get Free Report) and Avalon GloboCare (NASDAQ:ALBT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Volatility and Risk Humacyte has a beta of […]
December 31, 2023
Humacyte (NASDAQ:HUMA – Free Report) had its price target cut by Benchmark from $16.00 to $15.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. A number of other brokerages also recently weighed in on HUMA. Piper Sandler lowered their price objective on shares […]
December 4, 2023
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 6,090,000 shares, a growth of 10.7% from the October 31st total of 5,500,000 shares. Based on an average daily trading volume, of 583,200 shares, the short-interest ratio […]
October 16, 2023
-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease-...
October 1, 2023
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 5,250,000 shares, a growth of 38.2% from the August 31st total of 3,800,000 shares. Based on an average trading volume of 670,100 shares, the short-interest ratio is […]
September 4, 2023
Cantor Fitzgerald reaffirmed their overweight rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $6.00 price objective on the stock. Several other brokerages have also recently weighed in on HUMA. Benchmark reiterated a buy rating and issued a […]
August 28, 2023
Cantor Fitzgerald reaffirmed their overweight rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $6.00 target price on the stock. A number of other analysts have also weighed in on HUMA. Benchmark reaffirmed a buy rating and issued a […]
August 28, 2023
Cantor Fitzgerald restated their overweight rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the stock. A number of other research analysts also recently weighed in on HUMA. Piper Sandler raised Humacyte from an […]
August 26, 2023
Humacyte (NASDAQ:HUMA – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a research note issued to investors on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 68.07% from the company’s previous close. Other […]
August 22, 2023
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) CEO Laura E. Niklason sold 602,443 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $3.39, for a total transaction of $2,042,281.77. Following the sale, the chief executive officer now directly owns 8,191,140 shares of […]